Enleofen

Executive Summary

Enleofen is a Singapore-based preclinical biotechnology company founded in 2020, focused on developing first-in-class therapeutics targeting the interleukin-11 (IL-11) signaling pathway for fibro-inflammatory diseases. Leveraging a patient-centric discovery platform and strong human genetic evidence, the company aims to modulate fibrogenesis and organ dysfunction across multiple fibrotic conditions. Enleofen has built an extensive patent portfolio to protect its pipeline. With a small team of 10-50 employees, the company is in early preclinical stages and has not disclosed total funding or valuation. Its scientific approach addresses a significant unmet need in fibrosis and inflammatory diseases, where current therapies are limited. The company's progress will depend on advancing its lead candidates into IND-enabling studies and potentially into clinical trials.

Upcoming Catalysts (preview)

• Q1 2027Completion of IND-enabling studies for lead candidate40% success
• Q4 2026Announcement of Series A financing50% success
• Q3 2026Strategic partnership or licensing deal for IL-11 platform30% success